Christian Núñez1,2, Susana Ochoa3,4, Elena Huerta-Ramos3,4, Iris Baños3,4, Ana Barajas5, Montserrat Dolz4,6, Bernardo Sánchez6, Núria Del Cacho3, Judith Usall3,4. 1. Parc Sanitari Sant Joan de Déu, Sant Boi de Llobregat, Spain. c.nunez@pssjd.org. 2. Universitat de Barcelona, Barcelona, Spain. c.nunez@pssjd.org. 3. Parc Sanitari Sant Joan de Déu, Sant Boi de Llobregat, Spain. 4. Instituto de Salud Carlos III, Centro de Investigación en Red de Salud Mental (CIBERSAM), Madrid, Spain. 5. Research Unit, Centre d'Higiene Mental Les Corts, Barcelona, Spain. 6. Psychiatry Department, Hospital Sant Joan de Déu, Esplugues de Llobregat, Spain.
Abstract
RATIONALE: First episode patients and patients with schizophrenia exhibit increased rates of cannabis use compared to the general population. Contrary to what has been reported in studies with healthy people, most of the published studies so far have reported no impairments or even beneficial effects on neurocognition associated with cannabis consumption in psychotic patients. However, these studies did not address the effects of very high cannabis consumption. OBJECTIVES: Our aim in this study was to assess the effects on neurocognition of medium and heavy cannabis consumption in first psychotic episode patients. METHODS: A total of 74 patients were included in the study and assigned to three different groups according to their mean cannabis consumption during the last year (non-users, medium users, and heavy users). Participants were administered verbal memory and other neurocognitive tasks. RESULTS: Heavy cannabis users were significantly impaired in all the verbal memory measures with respect to non-users, including immediate (p = .026), short-term (p = .005), and long-term (p = .002) memory. There were no significant differences between medium and non-users. Moreover, non-users performed better than all cannabis users in the arithmetic task (p = .020). Heavy cannabis consumption was associated with more commission errors in the continuous performance task (CPT) (p = .008) and more time to complete trail making test A (TMT-A) (p = .008), compared to the group of medium users. CONCLUSIONS: Heavy cannabis consumption seems to impair verbal memory in first psychotic episode patients. Heavy users also perform worse than medium users in other neurocognitive tasks. Based on the results and the available evidence, a dose-related effect of cannabis consumption is suggested.
RATIONALE: First episode patients and patients with schizophrenia exhibit increased rates of cannabis use compared to the general population. Contrary to what has been reported in studies with healthy people, most of the published studies so far have reported no impairments or even beneficial effects on neurocognition associated with cannabis consumption in psychoticpatients. However, these studies did not address the effects of very high cannabis consumption. OBJECTIVES: Our aim in this study was to assess the effects on neurocognition of medium and heavy cannabis consumption in first psychotic episodepatients. METHODS: A total of 74 patients were included in the study and assigned to three different groups according to their mean cannabis consumption during the last year (non-users, medium users, and heavy users). Participants were administered verbal memory and other neurocognitive tasks. RESULTS: Heavy cannabis users were significantly impaired in all the verbal memory measures with respect to non-users, including immediate (p = .026), short-term (p = .005), and long-term (p = .002) memory. There were no significant differences between medium and non-users. Moreover, non-users performed better than all cannabis users in the arithmetic task (p = .020). Heavy cannabis consumption was associated with more commission errors in the continuous performance task (CPT) (p = .008) and more time to complete trail making test A (TMT-A) (p = .008), compared to the group of medium users. CONCLUSIONS: Heavy cannabis consumption seems to impair verbal memory in first psychotic episodepatients. Heavy users also perform worse than medium users in other neurocognitive tasks. Based on the results and the available evidence, a dose-related effect of cannabis consumption is suggested.
Entities:
Keywords:
Cannabis; First psychotic episode; Memory; Neurocognition; Psychosis
Authors: Nora D Volkow; Gene-Jack Wang; Frank Telang; Joanna S Fowler; David Alexoff; Jean Logan; Millard Jayne; Christopher Wong; Dardo Tomasi Journal: Proc Natl Acad Sci U S A Date: 2014-07-14 Impact factor: 11.205
Authors: Josefa María Moreno-Granados; Maite Ferrín; Dolores M Salcedo-Marín; Miguel Ruiz-Veguilla Journal: Rev Psiquiatr Salud Ment Date: 2013-07-02 Impact factor: 3.318
Authors: M Takahashi; O Shirakawa; K Toyooka; N Kitamura; T Hashimoto; K Maeda; S Koizumi; K Wakabayashi; H Takahashi; T Someya; H Nawa Journal: Mol Psychiatry Date: 2000-05 Impact factor: 15.992
Authors: P A Ringen; A Vaskinn; K Sundet; J A Engh; H Jónsdóttir; C Simonsen; S Friis; S Opjordsmoen; I Melle; O A Andreassen Journal: Psychol Med Date: 2009-11-06 Impact factor: 7.723
Authors: Eike Ahlers; Eric Hahn; Thi Minh Tam Ta; Elnaz Goudarzi; Michael Dettling; Andres H Neuhaus Journal: Psychopharmacology (Berl) Date: 2014-03-26 Impact factor: 4.530
Authors: Donald M Dougherty; Charles W Mathias; Michael A Dawes; R Michael Furr; Nora E Charles; Anthony Liguori; Erin E Shannon; Ashley Acheson Journal: Psychopharmacology (Berl) Date: 2012-11-09 Impact factor: 4.530
Authors: Hila Abush; Subroto Ghose; Erin A Van Enkevort; Brett A Clementz; Godfrey D Pearlson; John A Sweeney; Matcheri S Keshavan; Carol A Tamminga; Elena I Ivleva Journal: Psychiatry Res Neuroimaging Date: 2018-03-28 Impact factor: 2.376
Authors: Rachel A Rabin; Mera S Barr; Michelle S Goodman; Yarissa Herman; Konstantine K Zakzanis; Stephen J Kish; Michael Kiang; Gary Remington; Tony P George Journal: Neuropsychopharmacology Date: 2017-04-26 Impact factor: 7.853
Authors: Laura Ferraro; Caterina La Cascia; Diego Quattrone; Lucia Sideli; Domenica Matranga; Veronica Capuccio; Giada Tripoli; Charlotte Gayer-Anderson; Craig Morgan; Musa B Sami; Pak Sham; Lieuwe de Haan; Eva Velthorst; Hannah E Jongsma; James B Kirkbride; Bart P F Rutten; Alexander L Richards; Laura Roldan; Celso Arango; Miquel Bernardo; Julio Bobes; Julio Sanjuan; Jose Luis Santos; Manuel Arrojo; Ilaria Tarricone; Andrea Tortelli; Andrei Szöke; Cristina Marta Del-Ben; Jean-Paul Selten; Michael Lynskey; Peter B Jones; Jim Van Os; Daniele La Barbera; Robin M Murray; Marta Di Forti Journal: Schizophr Bull Date: 2020-04-10 Impact factor: 9.306
Authors: Mehdi Akbari; Mohammad Hossein Bahadori; Shahram Mohammadkhani; Daniel C Kolubinski; Ana V Nikčević; Marcantonio M Spada Journal: Addict Behav Rep Date: 2021-05-27